CB-010 to Be Evaluated in 2L LBCL; CB-011’s Ph1 Trial in MM Initiated; No Updates on Poseida’s Milestones for 2023; Caribou’s and Poseida’s Q1 2023 Earnings Call Summary
Here is a brief preview of this blast: On Tuesday, May 9, the following companies released their Q1 2023 results and business updates:
About The Author
The Celltelligence Team
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.